口服磷霉素氨丁三醇散治疗多重耐药菌所致慢性细菌性前列腺炎的临床效果  

Clinical effect of oral fosfomycin tromethamine powder in the treatment of chronic bacterial prostatitis caused by multidrug-resistant bacteria

作　　者：徐渊[1] XU Yuan(Jiangyin People's Hospital,Jiangyin 214400,China)

机构地区：[1]江苏省江阴市人民医院

出　　处：《临床医学研究与实践》2019年第32期33-34,41,共3页Clinical Research and Practice

摘　　要：目的分析口服磷霉素氨丁三醇散治疗多重耐药菌(MDR)所致慢性细菌性前列腺炎(CBP)的临床效果。方法选取2016年3月至2018年3月我院收治的44例CBP患者作为研究对象。患者均接受磷霉素氨丁三醇散治疗。观察治疗结束时患者的治愈情况和随访3、6个月的复发情况。结果本研究44例患者中,最常见的病原菌是大肠杆菌(65.9%),其次是克雷伯氏菌(13.6%)和粪肠球菌(13.6%)。大多数菌株为MDR(59.1%),22.7%的患者具有ESBL表型。44例中有33例对氟喹诺酮耐药,29例对甲氧苄啶/磺胺甲恶唑耐药,但均对磷霉素氨丁三醇散敏感。25例患者治疗持续6周,而其余19例患者由于前列腺钙化的存在,治疗延长至12周。治疗结束时以及随访3、6个月后的治愈率分别为81.8%、79.5%和72.7%。12例患者治疗失败。治疗结束时,8例患者出现腹泻,占比为18.2%,无其余不良反应发生。结论口服磷霉素氨丁三醇散治疗MDR致CBP的临床效果较好,且安全性高,值得临床推广。Objective To analyze the clinical effect of oral fosfomycin tromethamine powder in the treatment of chronic bacterial prostatitis(CBP) caused by multidrug-resistant bacteria(MDR). Methods A total of 44 patients with CBP admitted in our hospital from March 2016 to March 2018 were selected as the study objects. All patients were treated with fosfomycin tromethamine powder. The cure condition of the patients at the end of the treatment and the recurrence of the patients at 3 and 6 months follow-up were observed. Results Among the 44 patients, the most common pathogens were Escherichia coli(65.9%), followed by Klebsiella(13.6%) and Enterococcus faecalis(13.6%). Most of the strains were MDR(59.1%), and 22.7% of the patients had ESBL phenotype. Among the 44 cases, 33 patients were resistant to fluoroquinolone, 29 patients were resistant to trimethoprim/sulfamethoxazole, but all of them were sensitive to fosfomycin tromethamine powder. There were 25 patients treated for 6 weeks, while the remaining 19 patients were treated for 12 weeks because of prostate calcification. The cure rates at the end of treatment, 3 and 6 months follow-up were 81.8%, 79.5% and 72.7%. There were 12 patients failed in the treatment. At the end of treatment, 8 patients occurred diarrhea, the proportion was18.2%, and no other adverse reactions occurred. Conclusion Fosfomycin tromethamine powder has good efficacy and high safety in the treatment of MDR caused by CBP, which is worthy of clinical promotion.

关 键 词：慢性细菌性前列腺炎 磷霉素氨丁三醇散 多重耐药菌 

分 类 号：R697.33[医药卫生—泌尿科学]